Kyorin's DPP-4 inhibitor shows Phase II promise

The first Phase II data for Kyorin Pharmaceutical's DPP-4 inhibitor KRP-104 show statistically significant reductions in haemoglobin A1c (HbA1c) levels versus placebo when added to metformin therapy and administered either once or twice a day.